Abeona Therapeutics Inc. (ABEO)

7,47 -0,06 (-0,81%) In data: 10:32AM EDT. Mercato aperto.

Abeona Therapeutics Inc.

6555 Carnegie Avenue
4th Floor
Cleveland, OH 44103
United States
646 813 4701
https://www.abeonatherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 84

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Vishwas Seshadri M.B.A., Ph.D.	President, CEO & Director	1,49M	N/D	1977
Mr. Joseph Walter Vazzano CPA	Chief Financial Officer	920,85k	N/D	1985
Dr. Brendan M. O'Malley J.D., Ph.D.	Senior VP & General Counsel	802,95k	N/D	1970
Mr. Brian Kevany Ph.D.	Senior VP, CTO & CSO	N/D	N/D	N/D
Mr. Gregory Gin	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Alison Hardgrove	Vice President of Human Resources	N/D	N/D	N/D
Mr. Jon Voss	VP & Head of Quality	N/D	N/D	1960
Mr. Dmitriy Grachev M.D., Ph.D.	Chief Medical Officer	N/D	N/D	N/D
Dr. Madhav Vasanthavada M.B.A., Ph.D.	Senior VP, Chief Commercial Officer & Head of Business Development	N/D	N/D	N/D
Mr. Carl Denny	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Governance aziendale

L'ISS Governance QualityScore di Abeona Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.